Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The report serves as a notification of a transaction involving a Connected Person under the Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding director share awards rather than a financial results report.
Material Changes
The filing details a change in the interests of Dr. K. Slaoui (Connected Person) resulting from an award under the GlaxoSmithKline 2009 Performance Share Plan. On July 26, 2012, Dr. Slaoui received 1,692 American Depositary Shares (ADSs). The award was based on an ADS closing price of $44.90 per share.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or risk factors. It notes that the vesting of the awarded shares is subject to meeting performance criteria over a three-year period. The transaction was advised to the Company and the individual on July 27, 2012.
Investor Verification Points
- Verify the vesting schedule and specific performance criteria attached to the 1,692 ADSs awarded to Dr. K. Slaoui.
- Confirm the total aggregate holdings of Dr. K. Slaoui post-transaction to assess concentration of interest.
- Review the GlaxoSmithKline 2009 Performance Share Plan terms to understand the conditions for the three-year vesting period.